Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.
Summary
This bill would add a new section to the General Obligations Law to restrict overlapping ownership and control among insurance companies, pharmacy benefit managers (PBMs), and pharmacies. It defines key terms such as “pharmacy benefit manager” and “indirect control,” and then makes it unlawful for any person or entity to directly or indirectly own, operate, control, or direct the operation of an insurance company, a PBM, and a pharmacy, or any combination of those businesses.
The bill also requires divestment: any entity found to be in violation would have up to three years after the effective date to separate its interests. Enforcement would be vested in the Attorney General, who could bring a civil action and seek a $10,000 per day civil penalty, along with costs and reasonable attorneys’ fees. The act would take effect immediately.
Impact
If enacted, the bill would significantly alter New York law governing corporate relationships in the health insurance and prescription drug supply chain by prohibiting common ownership or control across insurers, PBMs, and pharmacies. It would create a new statutory restriction in the General Obligations Law and could force existing vertically integrated health care companies to restructure or divest holdings within three years. The Attorney General would gain explicit enforcement authority and penalty tools to police violations.
Sentiment
There is no recorded committee transcript or vote history available for this bill, so no direct legislative debate or formal sentiment can be measured from the provided materials. Based on the bill text and caption, the measure appears aimed at addressing concerns about market concentration and conflicts of interest in the pharmacy and insurance sectors, suggesting a consumer-protection and anti-consolidation rationale. However, without discussion or votes, support or opposition cannot be reliably characterized.
Contention
The main point of contention is likely to be whether prohibiting overlapping ownership among insurers, PBMs, and pharmacies is an appropriate way to address drug-pricing and access concerns. Supporters would likely argue that vertical integration creates conflicts of interest and can distort prescription drug costs and access, while opponents may contend that the bill is overly broad, could disrupt existing business models, and may reduce efficiencies or coordination in health care delivery. The divestment mandate and substantial daily penalties would also likely be contested by affected companies and industry groups.
Same As
Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.
Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.